The Expression of CD5 Outside Germinal Centers Is Associated

Total Page:16

File Type:pdf, Size:1020Kb

The Expression of CD5 Outside Germinal Centers Is Associated Expression of RAGs in Peripheral B Cells outside Germinal Centers Is Associated with the Expression of CD5 This information is current as Sophie Hillion, Alain Saraux, Pierre Youinou and Christophe of September 24, 2021. Jamin J Immunol 2005; 174:5553-5561; ; doi: 10.4049/jimmunol.174.9.5553 http://www.jimmunol.org/content/174/9/5553 Downloaded from References This article cites 58 articles, 26 of which you can access for free at: http://www.jimmunol.org/content/174/9/5553.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Expression of RAGs in Peripheral B Cells outside Germinal Centers Is Associated with the Expression of CD51 Sophie Hillion, Alain Saraux, Pierre Youinou,2 and Christophe Jamin Previous studies have indicated that mature B cells reactivate secondary V(D)J recombination inside and outside the germinal center (GC) of peripheral lymphoid organs. The nature of the B cells undergoing Ig rearrangement before they enter GC is unknown. In this study, we present evidence that activated mature CD5-positive human tonsil B cells coexpress both RAG1 and RAG2 mRNA and protein, and display DNA cleavage resulting from their recombinase activity. Furthermore, in vitro activation of CD5-negative naive mature B cells by IgR and CD40 cross-linking induces expression of CD5 on a subset of cells, and leads to the up-regulation of RAG1 and RAG2 only in cells turned positive for CD5. Thus, RAG gene expression is closely related to CD5 expression outside GCs. These data suggest that CD5 is associated with receptor revision in activated mature B cells and likely to promote expression of suitable IgR capable of initiating the GC reaction. The Journal of Immunology, 2005, 174: 5553–5561. Downloaded from econdary V(D)J rearrangement of Ig genes has been ex- process may generate cells bearing BCRs with various affinities. tensively described in immature bone marrow B cells. This The mutant cells will be selected during their differentiation into S process is referred to as receptor editing, contributes to the centrocytes Bm4 (CD38ϩϩIgDϪCD77Ϫ), depending on their BCR maintenance of immunological tolerance (1), and could rescue po- affinity for the Ag that is trapped as an immune complex on the tentially autoreactive B cells from apoptosis (2). Receptor editing surface of follicular dendritic cells. High-affinity Bm4 may interact http://www.jimmunol.org/ is initiated upon BCR engagement by Ag, resulting in the up- strongly with the Ag, process, and present it to GC T cells. These regulation of RAG gene expression, which then participates in ed- T cells will be induced to express CD40L, to secrete cytokines, and iting the autoreactive BCR-encoding Ig V(D)J rearrangements. to promote survival, proliferation, and isotype switching of the B Secondary V(D)J recombination has been shown to also occur in cells. These activated B cells will thus terminally differentiate ei- murine spleen and lymph node B cells in response to immunization ther into early memory (CD38ϩIgDϪ) and memory Bm5 (3–5). This peripheral V(D)J rearrangement, termed receptor revi- (CD38ϪIgDϪ) cells or into high-affinity Ab-forming cells. In con- sion, might contribute to the generation of high-affinity Abs in trast, autoreactive Bm4 cells would be deleted, because they do not germinal centers (GCs)3 following the process of somatic hyper- receive survival signal from T cells (11). Mutant Bm4 cells with mutation in response to stimulation by T-dependent Ags (6, 7). low affinity for Ag may have the potential to revise their receptor due by guest on September 24, 2021 There is evidence that human B cells also undergo secondary Ig to an increased RAG gene transcription (12). This could raise the recombination in the periphery (8, 9). Seven peripheral subpopu- affinity of the BCR for the Ag (8, 9). In this setting, strong BCR lations of B cells have been identified in human tonsils based on engagement would switch off RAG gene expression (13), suggesting the surface expression of CD38 and IgD in conjunction with other that receptor revision, which might be involved in affinity maturation markers (reviewed in Ref. 10), which have led to the proposition of Abs, will be terminated when BCR is strongly cross-linked. This of a model of T cell-dependent mature B cell differentiation. The process will permit the positive selection of high-affinity B cells to Ϫ ϩ Ϫ naive mature B (Bm) cells Bm1 (CD38 IgD CD23 ) and Bm2 terminally differentiate. ϩ ϩ ϩ (CD38 IgD CD23 ) would be activated in extrafollicular areas Recently, RAG expression in peripheral B cells has been ob- through interaction with interdigitating cells and Ag-specific T served outside the GC in a number of mouse models (14, 15) and cells. Activated blasts may either terminally differentiate into low- in humans (16). In the human model, RAG-positive B cells were affinity Ab-forming cells or become GC founder cells Bm2Ј found in the follicular mantle zone (FMZ) of the GCs where naive (CD38ϩϩIgDϩ). In GCs, Bm2Ј cells would differentiate into cen- ϩϩ Ϫ ϩ Bm1 and Bm2 cells are positioned (10). The T cell marker CD5 is troblast Bm3 (CD38 IgD CD77 ), in which somatic hypermu- expressed by Ͻ10% of the B cells in the adult human spleen and tation in V gene region might take place during proliferation. This Ͻ30% in lymph nodes (17). It is interesting that the CD5ϩ B cell population is also enriched in the FMZ (18, 19). Interestingly, in hen egg lysosyme (HEL)/anti-HEL transgenic Laboratory of Immunology, Brest University Medical School Hospital, Brest, France mice, CD5 expression is observed on mature anergic B cells (20). Received for publication August 25, 2004. Accepted for publication February Moreover, immature anergic B cells may activate the machinery 16, 2005. for V(D)J rearrangement to maintain B cell tolerance (21). Al- The costs of publication of this article were defrayed in part by the payment of page though CD5ϩ B cells have been shown (22) to express RAG in the charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. peritoneal cavity, it is unknown whether CD5 is involved in in- 1 This work was supported by grants from Ministe`re de l’Enseignement Supe´rieur et ducing the recombination process. Mature anergic B cells that fail de la Recherche and from Acade´mie Nationale Franc¸aise de Me´decine. to rearrange may express CD5 to negatively regulate the BCR and 2 Address correspondence and reprint requests to Prof. Pierre Youinou, Laboratory of avoid elimination, yet maintaining tolerance to self-Ag. However, Immunology, Brest University Medical School Hospital, BP 824, F 29609 Brest, by raising the threshold required for activation (23), CD5 may also France. E-mail address: [email protected] contribute to the triggering of the BCR revision. This view implies 3 Abbreviations used in this paper: GC, germinal center; Bm, mature B; FMZ, fol- licular mantle zone; HEL, hen egg lysosyme; biot, biotinylated; LM-PCR, ligation- that CD5 expression in the FMZ could be induced on mature B mediated PCR; ECD, energy-coupled dye. cells with BCR affinity insufficient to enter GC. RAG expression Copyright © 2005 by The American Association of Immunologists, Inc. 0022-1767/05/$02.00 5554 ASSOCIATION OF CD5 WITH BCR REVISION would, therefore, be found in activated cells expressing CD5. The 30 s at 94°C, 1 min at 56°C, and 1 min at 72°C with a final 10-min present study was designed to test this hypothesis. extension at 72°C. The second PCR round was for 35 cycles of 30 s at 94°C, 1 min at 56°C, and 1 min at 72°C with a final extension step at 72°C for 10 min. For the GAPDH RT-PCR amplification, only one round of PCR Materials and Methods was conducted for 40 cycles. Because the GAPDH primers spanned a short Preparation of B cells intron of 100 bp, genomic DNA could be amplified, but easily distinguish- able from the specific cDNA product. In such cases, samples were ex- Tonsils were obtained from 5- to 18-year-old children undergoing routine cluded from the RAG studies. Moreover, RAG1 and RAG2 first-round tonsillectomy. Tissues were minced up, diluted in PBS, and filtered to PCR primers spanned an intron at 5168 and 1174 bp, respectively, which deplete larger cells and clumps. Filtered cells were layered onto Ficoll- thus could not amplify contaminating genomic DNA. Taken together, these ϫ Hypaque density medium and centrifuged for 30 min at 450 g. Cells precautions certify that the PCR products originate specifically from were then incubated with neuraminidase-treated SRBC for1hat4°C. mRNA. RT-PCR products were analyzed on 2% agarose gels stained with Depletion of T cells was achieved by a second round of centrifugation on ethidium bromide.
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • B-Cell Receptor Pathway Inhibitors Affect CD20 Levels and Impair Antitumor Activity of Anti-CD20 Monoclonal Antibodies
    Letters to the Editor 1163 13 Kuruvilla J, Gutierrez M, Shah BD, Gabrail NY, de Nully Brown P, 14 Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Bjorkstrand B et al. Stone RM et al. Preliminary evidence of anti tumor activity of selinexor Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor via NF-kappaB. Blood 2008; 111: 4617–4626. of nuclear export (SINE) in patients (pts) with relapsed/refractory non 15BurgerJA,BurgerM,KippsTJ.Chronic lymphocytic leukemia B cells Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2013; express functional CXCR4 chemokine receptors that mediate spontaneous 122: 90. migration beneath bone marrow stromal cells. Blood 1999; 94: 3658–3667. Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies Leukemia (2014) 28, 1163–1167; doi:10.1038/leu.2014.12 also tested a primary MCL sample and upon treatment with BCR inhibitors observed a significant downregulation of surface CD20 levels and a trend towards impaired R-CDC and O-CDC (Supplementary Figure 1b). Moreover, we determined the Signaling via the aberrantly activated B-cell receptor (BCR) has a influence of BCR inhibitors on CD20 surface levels in a critical role in the pathogenesis of B-cell tumors by promoting series of 15 tumor cell lines, including Burkitt’s lymphoma (Ramos, survival and clonal expansion of malignant B cells.1,2 Multiple Daudi and BJAB), ALL (NALM-6), diffuse large B-cell lymphoma preclinical studies indicate that blocking various components of (BCR-dependent Ly-1, Ly-7, Ly-10, DHL-6, HBL-1, U2932 and the BCR signaling pathway holds a great therapeutic potential in BCR-independent Ly-4, Ly-19, Pfeiffer) and CLL (EHEB and MEC-1).
    [Show full text]
  • Altered Expression of CD63 and Exosomes in Scleroderma Dermal
    Journal of Dermatological Science 84 (2016) 30–39 Contents lists available at ScienceDirect Journal of Dermatological Science journal homepage: www.jdsjournal.com Altered expression of CD63 and exosomes in scleroderma dermal fibroblasts Kayo Nakamura, Masatoshi Jinnin*, Miho Harada, Hideo Kudo, Wakana Nakayama, Kuniko Inoue, Aki Ogata, Ikko Kajihara, Satoshi Fukushima, Hironobu Ihn Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan A R T I C L E I N F O A B S T R A C T Article history: Background: Exosomes are small vesicles shed from various cells. They contain proteins, lipids, and Received 6 January 2016 nucleic acids, and are regarded as a tool of cell-cell communication. Received in revised form 13 June 2016 Objectives: To reveal the putative role of exosomes in systemic sclerosis (SSc), and to elucidate the effect of Accepted 29 June 2016 exosomes on wound healing. Methods: The expression of common markers for exosomes (CD63, CD9, and CD81) and type I collagen Keywords: were examined with real-time PCR, immunohistochemical analysis, ELISA, immunoblotting, and flow Exosomes cytometry. The effect of serum-derived exosomes on wound healing was tested on full-thickness wounds CD63 in the mid-dorsal skin of BALB/c mice. Systemic sclerosis Results: The expression levels of CD63 as well as CD9 and CD81 tended to be increased in SSc dermal fibroblasts compared to normal fibroblasts. Increased exosomes in a cultured media of SSc fibroblasts stimulated the expression levels of type I collagen in normal fibroblasts. As the mechanism, collagen- related microRNA levels in SSc fibroblast-derived exosomes were dysregulated, indicating that both the amount and the content of exosomes were altered in SSc.
    [Show full text]
  • Combination Immunotherapy with Anti-CD20 and Anti-HLA-DR Monoclonal Antibodies Induces Synergistic Anti-Lymphoma Effects in Human Lymphoma Cell Lines
    UC Davis UC Davis Previously Published Works Title Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines Permalink https://escholarship.org/uc/item/8pk1f4nx Journal Leukemia & Lymphoma, 48(5) ISSN 1042-8194 Authors Tobin, Evan Denardo, Gerald Zhang, Nan et al. Publication Date 2007-05-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Rituximab & ChLym-1 Combined Immunotherapy Combination Immunotherapy with Anti-CD20 and Anti-HLA-DR Monoclonal Antibodies Induces Synergistic Anti-lymphoma Effects in Human Lymphoma Cell Lines Evan Tobin1, Gerald DeNardo1, Nan Zhang2, Alan L. Epstein2, Cathy Liu1 & Sally DeNardo1 1 Department of Internal Medicine, University of California Davis, CA, USA 2 Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA Running Title: Rituximab & ChLym-1 Combined Immunotherapy Keywords: Lymphoma; immunotherapy; rituximab; Lym-1; CD20; HLA-DR 1Address for correspondence: Gerald L. DeNardo, M.D. Division of Hematology and Oncology 1508 Alhambra Blvd., No. 3100 Sacramento, CA 95816 Telephone (916) 734-3787 Fax (916) 703-5014 E-mail: [email protected] 1 Rituximab & ChLym-1 Combined Immunotherapy ABSTRACT Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb1, combined with chLym-12, an anti- HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC3 and CDC4. There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone.
    [Show full text]
  • Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries with Limited Resources and for Triaging Cases Before
    AJCP /ORIGINAL ARTICLE Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers Downloaded from https://academic.oup.com/ajcp/article-abstract/145/5/687/2195691 by World Health Organization user on 09 January 2019 Maria Giulia Disanto, MD,1 Maria Raffaella Ambrosio, MD, PhD,2 Bruno Jim Rocca, MD, PhD,2 Hazem A. H. Ibrahim, FRCPath, PhD,1,3 Lorenzo Leoncini, MD, PhD,2 and Kikkeri N. Naresh, MD, FRCPath1 From the 1Department of Histopathology, Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom; 2Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy; and 3Department of Histopathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Key Words: Lymphoma; B-cell lymphoma; Immunohistochemistry; Diagnosis; Classification; Developing countries Am J Clin Pathol May 2016;145:687-695 DOI: 10.1093/AJCP/AQW060 ABSTRACT Lymphomas are a collection of different malignancies “arising” from lymphoid cells. They include about 49 entities, Objectives: Establish and validate optimal minimal and over 19 provisional entities and subsets.1 About 85% of immunohistochemistry panels for usage in a staged lymphomas are of B-cell origin. Precision in lymphoma diag- algorithmic manner for precise diagnosis of B-cell nosis requires expertise and infrastructure. The entities are lymphomas in countries with limited resources. Suggest defined based on morphology, immunohistochemistry (on short panels of immunostains to be used in referring units some occasions in situ hybridization), cytogenetics/fluores- that refer suspected lymphomas to specialist diagnostic cent in situ hybridization (FISH), molecular genetics and clin- centers in resourceful countries.
    [Show full text]
  • Aberrant Expression of Tetraspanin Molecules in B-Cell Chronic Lymphoproliferative Disorders and Its Correlation with Normal B-Cell Maturation
    Leukemia (2005) 19, 1376–1383 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation S Barrena1,2, J Almeida1,2, M Yunta1,ALo´pez1,2, N Ferna´ndez-Mosteirı´n3, M Giralt3, M Romero4, L Perdiguer5, M Delgado1, A Orfao1,2 and PA Lazo1 1Instituto de Biologı´a Molecular y Celular del Ca´ncer, Centro de Investigacio´n del Ca´ncer, Consejo Superior de Investigaciones Cientı´ficas-Universidad de Salamanca, Salamanca, Spain; 2Servicio de Citometrı´a, Universidad de Salamanca and Hospital Universitario de Salamanca, Salamanca, Spain; 3Servicio de Hematologı´a, Hospital Universitario Miguel Servet, Zaragoza, Spain; 4Hematologı´a-hemoterapia, Hospital Universitario Rı´o Hortega, Valladolid, Spain; and 5Servicio de Hematologı´a, Hospital de Alcan˜iz, Teruel, Spain Tetraspanin proteins form signaling complexes between them On the cell surface, tetraspanin antigens are present either as and with other membrane proteins and modulate cell adhesion free molecules or through interaction with other proteins.25,26 and migration properties. The surface expression of several tetraspanin antigens (CD9, CD37, CD53, CD63, and CD81), and These interacting proteins include other tetraspanins, integri- F 22,27–30F their interacting proteins (CD19, CD21, and HLA-DR) were ns particularly those with the b1 subunit HLA class II 31–33 34,35 analyzed during normal B-cell maturation and compared to a moleculesFeg HLA DR -, CD19, the T-cell recep- group of 67 B-cell neoplasias. Three patterns of tetraspanin tor36,37 and several other members of the immunoglobulin expression were identified in normal B cells.
    [Show full text]
  • In Situ Observation of Germinal Center Cell Apoptosis During a Secondary Immune Response
    J Clin Exp Hematopathol Vol. 46, No. 2, Nov 2006 Original Article In Situ Observation of Germinal Center Cell Apoptosis During a Secondary Immune Response Hito-aki Saitoh, Kunihiko Maeda, and Mitsunori Yamakawa Germinal centers are highly organized anatomic structures essential for the clonal expansion of germinal center (GC) B- cells and associated somatic hypermutation, isotype switching, selection of the high-affinity B-cells (affinity maturation), and elimination of irrelevant or autoreactive clones. The identification of cellular interactions and regulatory mechanisms controlling apoptosis within GCs is essential for a complete understanding of the cellular and molecular dynamics of the GC reaction. We performed a kinetic analysis of the apoptotic activity occurring within GCs of draining lymph nodes of mice immunized with sheep red blood cells (SRBC) after secondary stimulation. The apoptotic activity of GC cells can be divided into three distinct phases : 1) initial phase (within the first days after immunization), 2) reactive phase (from the 5th day to 15th day after secondary immunization), and 3) late phase (after the 15th day). Apoptosis decreased shortly after secondary immunization followed by an increase to peak after an additional 10 days. Finally, apoptosis of GC cells decreased to basal levels. Administration of apoptosis inhibitors decreased the amount of apoptosis during the reactive phase. These results suggest that the reactive phase may be the critical period in which clonal selection and cellular differentiation
    [Show full text]
  • Thymic Lymphoid Follicles in Autoimmune Diseases
    Keio J. Med. 20: 57-68. 1971 THYMIC LYMPHOID FOLLICLES IN AUTOIMMUNE DISEASES ‡U. HISTOLOGICAL, HISTOCHEMICAL AND ELECTRON MICROSCOPIC STUDIES NORIKAZU TAMAOKI, SONOKO HABU and TORU KAMEYA Department of Pathology, School of Medicine, Keio University, Tokyo (Received for publication May 8, 1971) Thymic lymphoid follicles have been known to occur frequently in patients of myasthenia gravis, Graves' disease and other autoimmune diseases, and occa sionally in the young subjects dying by accident.1,2,3,4,5 Spontaneous as well as experimental lymphoid follicles have also been described in the thymus of rodents 6,7,8,9 The presense of a thymic lymphoid follicle has been interpreted as an indication of an abnormal immunological reaction, since the thymus is not a site of antibody production under normal conditions. 10 The thymus is an epithelial organ separated from mesenchymal tissue by an epithelial barrier on the capsular surface and around the blood vessels.11,12,13,14 On the other hand, lymphoid follicles are usually found in the peripheral lymphoid tissue composed of mesenchymal reticular cells, such as lymph nodes, spleen andd lymphoid tissue associated with gut. The present study was intended to describe histological, histochemical and electron microscopic characteristics of thymic lymphoid follicles in order to con firm whether they were related to epithelial or mesenchymal elements and to clarify their histogenesis in the human thymus. MATERIALS AND METHODS The materials were the same biospied human thymuses as described in the previous report.5 Serial sections in some cases were made from paraffin blocks and stained alternatively with H & E and silver impregnation.
    [Show full text]
  • RA0358-C.5-IFU-RUO CD57 / B3GAT1 (Natural Killer Cell
    Instructions For Use RA0 35 8-C.5 -IFU -RUO Revision: 1 Rev. Date: Dec. 19, 2014 Page 1 of 2 P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 – Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com CD57 / B3GAT1 (Natural Killer Cell Marker); Clone NK/804 (Concentrate) Availability/Contents: Item # Volume RA0358-C.5 0.5 ml Description: Species: Mouse Immunogen: Recombinant human B3GAT1 protein Clone: NK/804 Isotype: IgM, kappa Entrez Gene ID: 27087 (Human) Hu Chromosome Loc.: 11q25 Synonyms: 3-Glucuronyltransferase 1; B3GAT1; Galactosylgalactosylxylosylprotein 3-beta- Glucuronosyltransferase 1; GLCATP; GlcUAT-P; Glucuronosyltransferase P; UDP GlcUA Glycoprotein beta 1, 3 Glucuronyltransferase. Mol. Weight of Antigen: ~110kDa Format: Bioreactor Concentrate with 0.05% Azide. Specificity: Anti-CD57 marks a subset of lymphocytes known as natural killer (NK) cells. Anti-CD57 also stains neuroendocrine cells and their derived tumors, including carcinoid tumors and medulloblastoma. Background: Follicular center cell lymphomas often contain many NK cells within the neoplastic follicles. Anti- CD57 can be useful in separating type B3 thymoma from thymic carcinoma when combined with a panel that includes antibodies against GLUT1, CD5, and CEA. Species Reactivity: Human. Does not react with Rat. Others not known. Positive Control: Lymph node or tonsil. Cellular Localization: Cell surface Titer/ Working Dilution: Immunohistochemistry (Frozen and Formalin-fixed): 1:50-1:100 Flow Cytometry: 5-10 µl/million cells Immunofluorescence: 1:50-1:100 Western Blotting: 1:100-1:200 Microbiological State: This product is not sterile. 8° C Storage: 2° C C ScyTek Laboratories, Inc. 205 South 600 West P EmergoEurope (31)(0) 70 345-8570 Logan, UT 84321 Molsnstraat 15 Doc: IFU-Template2-8rev2 U.S.A.
    [Show full text]
  • Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367
    Medicare Local Coverage Determination Policy Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367 CMS Policy for Alaska, Arizona, Idaho, Montana, North Dakota, Medically Supportive Oregon, South Dakota, Utah, Washington, and Wyoming ICD Codes are listed Local policies are determined by the performing test location. This is determined by the state on subsequent page(s) in which your performing laboratory resides and where your testing is commonly performed. of this document. Coverage Indications, Limitations, and/or Medical Necessity Flow cytometry (FCM) is a complex process to examine blood, body fluids, CSF, bone marrow, lymph node, tonsil, spleen and other solid tissues. The use of peripheral blood and fine needle aspirate material avoids more invasive procedures for diagnosis. A flow cytometer evaluates the physical and/or chemical characteristics of single cells as the cells pass individually in a fluid stream through a measuring device. Surface receptors, intracellular molecules, and DNA bind with fluorescent dyes that allow detection and evaluation. When light of one wave length excites electrons of certain chemicals to energy levels above their ground state and upon return to ground state emits light of a longer wavelength, fluorescence is produced. A flow cytometer detects cell characteristics by measuring the fluorescence produced by fluorochromes conjugated either directly with cell components or conjugated to antibodies directed against cell components. Indications • Cytopenias and Hypercellular Hematolymphoid Disorders Hematolymphoid neoplasia can present with cytopenias (anemia, leucopenia and/or thrombocytopenia) or elevated leukocyte counts. If medical review and preliminary laboratory testing fails to reveal a cause, bone marrow aspiration and biopsy are indicated to rule out an infiltrative process or a stem cell disorder.
    [Show full text]
  • Germinal Center Formation Motif Signaling in B Cells and Reduced
    Altered Regulation of FcγRII on Aged Follicular Dendritic Cells Correlates with Immunoreceptor Tyrosine-Based Inhibition Motif Signaling in B Cells and Reduced This information is current as Germinal Center Formation of October 3, 2021. Yüksel Aydar, Péter Balogh, John G. Tew and Andras K. Szakal J Immunol 2003; 171:5975-5987; ; doi: 10.4049/jimmunol.171.11.5975 Downloaded from http://www.jimmunol.org/content/171/11/5975 References This article cites 47 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/171/11/5975.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 3, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Altered Regulation of Fc␥RII on Aged Follicular Dendritic Cells Correlates with Immunoreceptor Tyrosine-Based Inhibition Motif Signaling in B Cells and Reduced Germinal Center Formation1 Yu¨ksel Aydar,* Pe´ter Balogh,* John G.
    [Show full text]
  • Centers Differentiation Stages in Human Germinal Patterns Reflect
    Cutting Edge: Polycomb Gene Expression Patterns Reflect Distinct B Cell Differentiation Stages in Human Germinal Centers This information is current as of September 27, 2021. Frank M. Raaphorst, Folkert J. van Kemenade, Elly Fieret, Karien M. Hamer, David P. E. Satijn, Arie P. Otte and Chris J. L. M. Meijer J Immunol 2000; 164:1-4; ; doi: 10.4049/jimmunol.164.1.1 Downloaded from http://www.jimmunol.org/content/164/1/1 References This article cites 22 articles, 11 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/164/1/1.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. c Cutting Edge: Polycomb Gene Expression Patterns Reflect Distinct B Cell Differentiation Stages in Human Germinal Centers Frank M. Raaphorst,1* Folkert J. van Kemenade,* Elly Fieret,* Karien M.
    [Show full text]